Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.
Brand Name : SCI-110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : SciSparc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?